Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Locke F, Siddiqi T, Jacobson C, Ghobadi A, Ahmed S, Miklos D, Perales M, Munoz J, Fingrut W, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza A, Abid M, Hong S, Majhail N, Kharfan-Dabaja M, Khurana A, Badar T, Lin Y, Bennani N, Herr M, Hu Z, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini M. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood 2024, 143: 2722-2734. PMID: 38635762, PMCID: PMC11251200, DOI: 10.1182/blood.2023023447.Peer-Reviewed Original ResearchChimeric antigen receptorR/R LBCLNH-White patientsAxicabtagene ciloleucelZUMA-1ZUMA-7Autologous anti-CD19 chimeric antigen receptorCenter for International Blood and Marrow Transplant Research databaseAnti-CD19 chimeric antigen receptorHazard ratioOdds ratioLarge B-cell lymphomaProgression-free survivalT-cell therapyDuration of responseB-cell lymphomaCytokine release syndromeNH WhitesNH Black patientsAdjusted odds ratiosClinical trial settingClinical trial outcomesOverall survivalT cellsLBCL